Maintenance with Interferon Alpha in Myeloma

  • H. Ludwig
  • E. Fritz
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 39)

Abstract

Although IFN maintenance treatment is routinely used in many myeloma treatment centers, its clinical efficacy is still a matter of controversy. IFN, a biologic response modifier, inhibits myeloma cell growth and stimulates important functions of the immune system. Randomized clinical trials have yielded ambiguous results regarding improvements of remission duration and survival times. However, a meta-analysis of all available randomized studies which compared IFN maintenance treatment with untreated controls (involving 1213 myeloma patients) showed small but significant gains in both relapse-free and overall survival. Several studies report beneficial effects of IFN maintenance treatment after high-dose therapy with autologous bone marrow or stem cell transplantation. The most frequently observed adverse effects of IFN maintenance therapy are fever and flu-like symptoms, which mainly occur during the early treatment phase, and fatigue. When patients are given the opportunity to state their personal preferences, the majority of them will opt for IFN maintenance treatment if the expected median gains in relapse-free or overall survival are 6 months or more. Patients who agree to the treatment tend to be younger, to have had personal experience with IFN, and to be in more advanced myeloma stages. We recommend IFN maintenance treatment in myeloma patients with low tumor burden, such as patients in complete remission after high-dose treatment and bone marrow or peripheral stem cell transplantation.

Keywords

Fatigue Toxicity Leukemia Corticosteroid Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Creasey AA, Bartholomew JC, Merigan TC (1980) Role of G0–G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77: 1471–75PubMedCrossRefGoogle Scholar
  2. 2.
    Horoszewicz JS, Leong SS, Carter WS (1979) Non cycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 206: 1091–3PubMedCrossRefGoogle Scholar
  3. 3.
    Einhorn S, Strander H (1978) Interferon therapy for neoplastic diseases in man: in vitro and in vivo studies. Adv Exp Med Biol 110: 159–74PubMedGoogle Scholar
  4. 4.
    Brenning G, Jernberg H, Gidlund M, Sjoeberg 0, Nilsson K (1986) The effect of alpha and gam-ma-interferon on proliferation and production of IgE and beta 2-micro-globulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline. Scand J Haematol 37: 280–8PubMedGoogle Scholar
  5. 5.
    Ludwig H, Swetly P (1980) In vitro inhibitory effect of interferon on multiple myeloma stem cells. Cancer Immunol Immunther 9: 139–43Google Scholar
  6. 6.
    Jernberg-Wiklund H, Pettersson M, Nilsson K (1991) Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 46: 231–9PubMedCrossRefGoogle Scholar
  7. 7.
    Senn CC (1984) Biochemical pathways in interferon action. Pharmacol Ther 24: 235–40CrossRefGoogle Scholar
  8. 8.
    Princler GL, Brini AT, Kong H (1990) IFN-alpha down-regulates th IL-6 receptor (IL-6R) by induction of endogenous IL-6. Lymphokine Res 9: 570Google Scholar
  9. 9.
    Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B (1991) IFN-alpha induces auto-crine production of IL-6 in myeloma cell lines. J Immunol 147: 4402–7PubMedGoogle Scholar
  10. 10.
    Kimchi A (1987) Autocrine interferon and the suppression of the c-myc nuclear oncogene. Interferon 8: 85–110PubMedGoogle Scholar
  11. 11.
    Samid D, Chang EH, Friedman RM (1985) Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon. Biochem Biophys Res Commun 126: 509–16PubMedCrossRefGoogle Scholar
  12. 12.
    Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, Strander H (1982) Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 30: 167–72Google Scholar
  13. 13.
    Jett R, Mantovani A, Herberman RB (1980) Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol 54: 425–32PubMedCrossRefGoogle Scholar
  14. 14.
    Osterborg A, Nilsson B, Björkholm M, Holm G, Mellstedt H (1990) Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 45: 153–7PubMedCrossRefGoogle Scholar
  15. 15.
    De Maeyer-Guignard J, De Maeyer E (1985) Immunomodulation by interferons: recent developments. Interferon 6: 69–91PubMedGoogle Scholar
  16. 16.
    Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T (1989) Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58: 729–39PubMedCrossRefGoogle Scholar
  17. 17.
    Grander D, von Stedingk LV, von Stedingk M, Wasserman J, Einhorn S (1991) Influence of interferon on antibody production and viability of malignant cells from patients with multiple myeloma. Eur J Haematol 46: 17–25PubMedCrossRefGoogle Scholar
  18. 18.
    Teichmann JV, Sieber G, Ludwig WD, Ruehl H (1989) Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients. Cancer 63: 1990–3PubMedCrossRefGoogle Scholar
  19. 19.
    Mandelli F, Avvisati G, Amadori S, et al. (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New Engl J Med 322: 1430–4PubMedCrossRefGoogle Scholar
  20. 20.
    Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J (1994) a-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group study. J Clin Oncol 12: 2405–14Google Scholar
  21. 21.
    Browman GP, Bergsagel D, Sicheri D, et al. (1995) Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13: 2354–60PubMedGoogle Scholar
  22. 22.
    Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G (1995) Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group. Br J Haematol 89: 561–8Google Scholar
  23. 23.
    Peest D, Deicher H, Coldewey R, et al. (1995) A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 31A: 146–51Google Scholar
  24. 24.
    Ludwig H, Cohen AM, Polliack A, et al. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Ann Oncol 6: 467–76PubMedGoogle Scholar
  25. 25.
    Powles R, Raje N, Cunningham D, et al. (1995) Maintenance therapy for remission in myeloma with intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 13 (suppl2): 114–17PubMedGoogle Scholar
  26. 26.
    McSweeney EN, Tobias JS, Blackman G, Goldstone AH, Richards JDM (1993) Double hemibody irradiation ( DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. Clin Oncol 5: 378–83Google Scholar
  27. 27.
    Jagannath S, Crowley J, Vesole D, et al. (1994) Interferon-alpha (IFN) may improve event-free (EFS) and overall survival (OS) in multiple myeloma (MM) following double autotransplants (DAT). Proc Annu Meet Am Soc Clin Oncol 14: A1354 (abstract)Google Scholar
  28. 28.
    Berenson J, Schiller G, Vescio R, et al. (1994) CD34-selected peripheral stem cell transplantation in multiple myeloma. Ann Oncol 5 (Suppl 8): 126 (abstract)Google Scholar
  29. 29.
    Björkstrand B, Ljungman P, Bird JM, et al. (1995) Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 13 (suppl 2): 140–6PubMedCrossRefGoogle Scholar
  30. 30.
    Harousseau L, Attal M, Divine M, et al. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 85: 3077–85PubMedGoogle Scholar
  31. 31.
    Samson D,Volin L, Schanz U, Bosi A, Gahrtron G (1996) Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 17: 759–62Google Scholar
  32. 32.
    Zervas K, Pouli A, Perifanis V, et al. (1996) Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol 57: 142–8Google Scholar
  33. 33.
    Salmon SE, Crowley JJ (1997) Alpha interferon plus alternate day prednisone (IFN/P) improves remission maintenance duration in multiple myeloma (MM) compared to IFN alone. Proc ASCO 16: 13a (abstract)Google Scholar
  34. 34.
    Fossa SD, Gunderson R, Moe B (1990) Recombinant interferon alpha combined with prednisone in metastatic renal cell carcinoma: Reduced toxicity without reduction of the response rate. - A phase II study. Cancer 65: 2451–4Google Scholar
  35. 35.
    Chauhan D, Uchiyama H, Akbarali Y, et al. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104–12.PubMedGoogle Scholar
  36. 36.
    Ray A, Zhang DH, Siegel MD, Ray P (1995) Regulation of interleukin-6 gene expression by steroids. Ann N Y Acad Sci 76279–87.Google Scholar
  37. 37.
    Wisloff F, Hjorth M, Kaasa S, Westin J (1996) Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 94: 324–32Google Scholar
  38. 38.
    Ludwig H, Fritz E, Neuda J, Durk BGM (1997) Patient preferences for interferon-alpha in multiple myeloma. J Clin Oncol 15: 1672–9PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • H. Ludwig
    • 1
  • E. Fritz
    • 1
  1. 1.1st Dept. of Medicine and OncologyWilhelminenspitalViennaAustria

Personalised recommendations